1. Home
  2. SII vs AVDL Comparison

SII vs AVDL Comparison

Compare SII & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprott Inc.

SII

Sprott Inc.

HOLD

Current Price

$98.01

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Avadel Pharmaceuticals plc

AVDL

Avadel Pharmaceuticals plc

HOLD

Current Price

$21.55

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SII
AVDL
Founded
2008
2015
Country
Canada
Ireland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
SII
AVDL
Price
$98.01
$21.55
Analyst Decision
Hold
Buy
Analyst Count
1
9
Target Price
$132.00
$18.38
AVG Volume (30 Days)
149.8K
1.6M
Earning Date
11-05-2025
11-04-2025
Dividend Yield
1.31%
N/A
EPS Growth
7.97
N/A
EPS
1.96
N/A
Revenue
$216,267,000.00
$248,517,000.00
Revenue This Year
$27.96
$65.47
Revenue Next Year
$4.65
$30.88
P/E Ratio
$50.70
N/A
Revenue Growth
22.38
79.88
52 Week Low
$39.33
$6.38
52 Week High
$102.30
$23.57

Technical Indicators

Market Signals
Indicator
SII
AVDL
Relative Strength Index (RSI) 62.12 59.13
Support Level $97.36 $21.50
Resistance Level $101.27 $21.67
Average True Range (ATR) 3.19 0.12
MACD 0.21 -0.09
Stochastic Oscillator 69.83 55.88

Price Performance

Historical Comparison
SII
AVDL

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: